Conditions: Type 2 Diabetes Mellitus
Keywords: TA-7284 JNJ-28431754 Canagliflozin Sodium Glucose Co-transporter (SGLT2 inhibitor)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 272
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.

Detailed description:
This is a randomized, 3-arm, parallel group, double blind study to evaluate the efficacy and safety of TA-7284 in Japanese patients with Type 2 diabetes mellitus, who are not optimally controlled on diet and exercise. The patients will receive either TA-7284-Low, TA-7284-High or Placebo orally alone for 24 weeks.

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: TA-7284 Low intervention 2: TA-7284 High intervention 3: Placebo
Intervention descriptions: intervention 1: The patients will receive TA-7284-Low orally for 24 weeks. intervention 2: The patients will receive TA-7284-High orally for 24 weeks. intervention 3: The patients will receive Placebo orally for 24 weeks.

Protocol document: